Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A

Experimental Hematology

Volumn 40, Issue 8, 2012, Pages

  Blake, Stephen J ^a,b,c   Hughes, Timothy P ^a,b   Lyons, A Bruce ^a,b,d  

^a SA Pathology ^*  (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DASATINIB; IMATINIB;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 84864017153     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.04.003     Document Type: Article

References (32)

1. Talpaz M., Shah N.P., Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541.
2. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
3. Schade A.E., Schieven G.L., Townsend R., et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008, 111:1366-1377.
4. Seggewiss R., Lore K., Greiner E., et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005, 105:2473-2479.
5. Fruman D.A., Klee C.B., Bierer B.E., Burakoff S.J. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci U S A 1992, 89:3686-3690.
6. Kahan B.D. Cyclosporine. N Engl J Med 1989, 321:1725-1738.
7. Huang Y., Comiskey E.O., Dupree R.S., Li S., Koleske A.J., Burkhardt J.K. The c-Abl tyrosine kinase regulates actin remodeling at the immune synapse. Blood 2008, 112:111-119.
8. Palacios E.H., Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 2004, 23:7990-8000.
9. Molina T.J., Kishihara K., Siderovski D.P., et al. Profound block in thymocyte development in mice lacking p56lck. Nature 1992, 357:161-164.
10. Manley P.W., Cowan-Jacob S.W., Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta 2005, 1754:3-13.
11. Blake S.J., Lyons A.B., Hughes T.P. Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro. J Cell Mol Med 2009, 13:599-601.
12. Chen J., Schmitt A., Chen B., et al. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signaling. J Cell Mol Med 2008, 12:2107-2118.
13. Blake S., Hughes T.P., Mayrhofer G., Lyons A.B. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol 2008, 127:330-339.
14. Fraser C.K., Blake S.J., Diener K.R., et al. Dasatinib inhibits recombinant viral antigen-specific murine CD4(+) and CD8(+) T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp Hematol 2009, 37:256-265.
15. Fei F., Yu Y., Schmitt A., et al. Dasatinib exerts an immunosuppressive effect on CD8(+) T cells specific for viral and leukemia antigens. Exp Hematol 2008, 36:1297-1308.
16. Weichsel R., Dix C., Wooldridge L., et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 2008, 14:2484-2491.
17. Sillaber C., Herrmann H., Bennett K., et al. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest 2009, 39:1098-1109.
18. Torres H.A., Chemaly R.F. Viral infection or reactivation in patients during treatment with dasatinib: a call for screening?. Leuk Lymphoma 2007, 48:2308-2309.
19. Porter C.C., Gregory M.A., Zaberezhnyy V., Klawitter J., Christians U., DeGregori J. The addition of cyclosporine to dasatinib therapy of murine Bcr-Abl+ leukemia improves disease control independent of altered pharmacokinetics. ASH Annual Meeting Abstracts 2010, 116:600.
20. Gregory M.A., Phang T.L., Neviani P., et al. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell 2010, 18:74-87.
21. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
22. Lyons A.B. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods 2000, 243:147-154.
23. Lyons A.B., Parish C.R. Determination of lymphocyte division by flow cytometry. J Immunol Methods 1994, 171:131-137.
24. Flaig T.W., Su L.J., Harrison G., Agarwal R., Glode L.M. Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. Int J Cancer 2007, 120:2028-2033.
25. Tallarida R.J. Drug synergism: its detection and applications. J Pharmacol Exp Ther 2001, 298:865-872.
26. Fei F., Yu Y., Schmitt A., et al. Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells. Br J Haematol 2009, 144:195-205.
27. Chen C., Lee W.H., Yun P., Snow P., Liu C.P. Induction of autoantigen-specific Th2 and Tr1 regulatory T cells and modulation of autoimmune diabetes. J Immunol 2003, 171:733-744.
28. Hiwase D.K., Saunders V., Hewett D., et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 2008, 14:3881-3888.
29. Ottmann O., Dombret H., Martinelli G., et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007, 110:2309-2315.
30. Mustjoki S., Ekblom M., Arstila T.P., et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009, 23:1398-1405.
31. de Lavallade H., Punnialingam S., Milojkovic D., et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 2008, 141:745-747.
32. Kreutzman A., Juvonen V., Kairisto V., et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010, 116:772-782.